Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Arvinas has a consensus “Hold” rating from 11 analysts: five recommend buying, four recommend holding, and two recommend selling. The average 12-month price target is $14.17, above the stock’s reported $8.45 price.
• ARVN shares were down 3.0%, with a market capitalization of approximately $545 million and a 52-week range of $6.97 to $14.51.
• The company reported quarterly revenue of $249.7 million, up 1,014.7% year over year, and earnings of $2.58 per share, significantly exceeding analyst expectations. Institutional investors own 95.19% of outstanding shares, while insiders own 7.30%.

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have received an average rating of "Hold" from the eleven analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $14.1667.

A number of brokerages have recently commented on ARVN. BTIG Research reaffirmed a "buy" rating and issued a $18.00 price target on shares of Arvinas in a research note on Tuesday, August 4th. Zacks Research cut shares of Arvinas from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 3rd. Weiss Ratings upgraded shares of Arvinas from a "sell (e+)" rating to a "sell (d)" rating in a report on Thursday, August 13th. Wedbush upped their target price on shares of Arvinas from $11.00 to $12.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Finally, Stephens reissued an "overweight" rating and set a $18.00 price target on shares of Arvinas in a research report on Wednesday, June 3rd.

Insider Activity at Arvinas

In related news, CFO Andrew Saik sold 5,696 shares of the firm's stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $8.16, for a total transaction of $46,479.36. Following the sale, the chief financial officer owned 187,432 shares of the company's stock, valued at approximately $1,529,445.12. This trade represents a 2.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arvinas

Several large investors have recently modified their holdings of the business. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Arvinas by 371.0% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 70,650 shares of the company's stock valued at $838,000 after purchasing an additional 55,650 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Arvinas during the second quarter worth about $1,182,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Arvinas in the 2nd quarter valued at approximately $1,388,000. Armistice Capital LLC lifted its stake in Arvinas by 50.0% in the 4th quarter. Armistice Capital LLC now owns 1,800,000 shares of the company's stock valued at $21,348,000 after acquiring an additional 600,000 shares in the last quarter. Finally, Man Group plc bought a new stake in Arvinas in the 2nd quarter valued at approximately $2,128,000. 95.19% of the stock is currently owned by institutional investors.

Arvinas Stock Down 3.0%

ARVN stock opened at $8.45 on Friday. Arvinas has a twelve month low of $6.97 and a twelve month high of $14.51. The company has a market cap of $545.19 million, a P/E ratio of 84.51 and a beta of 1.75. The business's fifty day moving average is $8.74 and its 200-day moving average is $9.61.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $2.95. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The business had revenue of $249.70 million during the quarter, compared to analysts' expectations of $60.71 million. During the same period in the previous year, the firm earned ($0.84) earnings per share. The firm's quarterly revenue was up 1014.7% compared to the same quarter last year. Research analysts anticipate that Arvinas will post 0.05 earnings per share for the current fiscal year.

About Arvinas

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.